Vivoryon Therapeutics N.V. said its cash and cash equivalents are sufficient to fund operations into the fourth quarter of 2026.
The clinical-stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, said it presented compelling kidney function data and a meta-analysis at the World Congress of Nephrology that underpins plans to advance varoglutamstat into a Phase 2b study in stage 3b/4 diabetic kidney disease (DKD).
"We have consistently shown that varoglutamstat improves kidney function in elderly patients, in particular those with diabetes," said Frank Weber, MD, CEO.
Vivoryon reported that two independent randomized placebo-controlled Phase 2 studies, VIVIAD and VIVA-MIND, produced statistically significant and clinically meaningful improvements in estimated glomerular filtration rate (eGFR) versus placebo, with a pronounced effect in elderly participants with diabetes and in those with lower baseline eGFR (mean 60 mL/min/1.73m2).
Pre-clinical DKD mouse-model data presented alongside the clinical analyses showed significant improvements in inflammation, glomerulosclerosis and kidney function, and a webcast published in April added mechanistic data implicating QPCT/QPCTL in collagen maturation and positive effects on podocytes.
The company said initiation of the planned Phase 2b study and all future trials remains subject to additional funding and/or partnership and that it is in active due diligence with multiple potential partners and strategic investors.
There were no revenues in Q1 2026, research and development expenses fell to EUR 0.9 million from EUR 1.2 million a year earlier, and the net loss for the quarter was EUR 1.8 million versus EUR 2.5 million in Q1 2025.
Cash and cash equivalents were EUR 4.0 million at March 31, down from EUR 5.6 million at December 31, 2025, and the company said its runway guidance does not assume additional funding such as proceeds from the SEPA or other financing transactions.
Vivoryon said it expects continued operating losses and the need to raise further capital, and it will host a financial and business update alongside its H1 results, anticipated in August.
